Oxylipins are metabolites derived from lipid peroxidation. The plant oxylipin methyl jasmonate (MJ) shows cytotoxic activity against cancer cell lines of various origins, with ATP-depletion being one of the mechanisms responsible for this effect. The cytotoxic activity of oxylipins (OXLs) isolated from the microalgae Chlamydomonas debaryana (13-HOTE) and Nannochloropsis gaditana (15-HEPE) was higher against UACC-62 (melanoma) than towards HT-29 (colon adenocarcinoma) cells. OXLs lowered the ATP levels of HT-29 and UACC-62 cells, but the effect was higher on the second cell line, which had higher basal ATP. This result proves a link between the cytotoxicity and the capability of these compounds to deplete ATP. In addition, the combination of 13-HOTE with the anticancer drug 5-fluorouracil (5-FU) induced a synergistic toxicity against HT-29 cells. These results highlight the therapeutic potential of oxylipins derived from microalgae.
MorinC., RousseauE., FortinS. (2013) Anti-proliferative effects of a new docosapentaenoic acid monoacylglyceride in colorectal carcinoma cells. Prostaglandins, Leukotrienes and Essential Fatty Acids, 89, 203–213.
4.
PennyM.K., WilliamS.H., LawrenceJ.A. (2003) Omega-3 fatty acids and cardiovascular disease. New recommendations from the American Heart Association. Arteriosclerosis, Thrombosis and Vascular Biology, 23, 151–152.
5.
de los ReyesC., Ávila-RománJ., OrtegaM.J., de la JaraA., García-MauriñoS., MotilvaV., ZubíaE. (2014) Oxylipins from the microalgae Chlamydomonas debaryana and Nannochlorosis gaditana and their activity as TNF-α inhibitors. Phytochemistry, 102, 152–161.
6.
Ávila-RománJ., TaleroE., AlcaideA., de los ReyesC., ZubíaE., García-MauriñoS., MotilvaV. (2014) Preventive effect of the microalga Chlamydomonas debaryana in the acute phase of experimental colitis in rats. British Journal of Nutrition, 112, 1055–1064.
7.
VellosilloT., MartínezM., LópezM.A., VicenteJ., CascónT., DolanL., HambergM., CastresanaC. (2007) Oxylipins produced by the 9-lipoxygenase pathway in Arabidopsis regulate lateral root development and defense responses through a specific signaling cascade. The Plant Cell, 19, 831–846.
8.
SantinoA., TaurinoM., De DomenicoS., BonsegnaS., PoltronieriP., PastorV., FlorsV. (2013) Jasmonate signaling in plant development and defense response to multiple (a)biotic stresses. Plant Cell Reports, 32, 1085–1098.
9.
FlescherE. (2005) Jasmonates-a new family of anti-cancer agents. Anticancer Drugs, 16, 911–916.
10.
FlescherE. (2007) Jasmonates in cancer therapy. Cancer Letters, 245, 1–10.
11.
RavivZ., CohenS., Reischer-PelechD. (2013) The anti-cancer activities of jasmonates. Cancer Chemotherapy and Pharmacology, 71, 275–285.
12.
Ghasemi PirbaloutiA., SajjadiS.E., ParangK. (2014) A review (research and patents) on jasmonic acid and its derivatives. Archiv der Pharmazie (Weinheim), 347, 229–239.
13.
CohenS., FlescherE. (2009) Methyl jasmonate: a plant stress hormone as an anti-cancer drug. Phytochemistry, 70, 1600–1609.
14.
KlippelS., JakubikovaJ., DelmoreJ., OoiM., McMillinD., KastritisE., LaubachJ., RichardsonP.G., AndersonK.C., MitsiadesC.S. (2012) Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells. British Journal of Haematology, 159, 340–351.
15.
WasternackC. (2007) Jasmonates: an update on biosynthesis, signal transduction and action in plant stress response, growth and development. Annals of Botany, 100, 681–697.
16.
ReischerD., HeyfetsA., ShimonyS., NordenbergJ., KashmanY., FlescherE. (2007) Effects of natural and novel synthetic jasmonates in experimental metastatic melanoma. British Journal of Pharmacology, 150, 738–749.
17.
RotemR., HeyfetsA., FingrutO., BlicksteinD., ShaklaiM., FlescherE. (2005) Jasmonates: novel anticancer agents acting directly and selectively on human cancer cell mitochondria. Cancer Research, 65, 1984–1993.
18.
EliaU., FlescherE. (2013) Combined chemotherapy or biotherapy with jasmonates: targeting energy metabolism for cancer treatment. Current Pharmaceutical Biotechnology, 14, 331–341.
19.
CesariI.M., CarvalhoE., Figueiredo RodriguesM., Mendonça BdosS., AmôedoN.D., RumjanekF.D. (2014) Methyl jasmonate: putative mechanisms of action on cancer cells cycle, metabolism, and apoptosis. International Journal of Cell Biology, 2014, Article ID 572097. doi: 10.1155/2014/572097.
20.
SkehanP., StorengR., ScudieroD., MonksA., McMahonJ., VisticaD., WarrenJ.T., BokeshH., KenneyS., BoydM.R. (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. Journal of the National Cancer Institute, 82, 1107–1112.
21.
MosmannT. (1983) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. Journal of Immunological Methods, 65, 55–63.
22.
DeckerT., Lohmann-MatthesM. (1988) A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. Journal of Immunological Methods, 15, 61–69.
23.
LeachF.R. (1981) ATP determination with firefly luciferase. Journal of Applied Biochemistry, 3, 473–517.
24.
ChouT.C. (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies, Pharmacological Reviews, 58, 621–681.
25.
TaylorE.W. (1965) The mechanism of colchicine inhibition of mitosis: I. Kinetics of inhibition and the binding of H3-colchicine. The Journal of Cell Biology, 25, 145–160.
26.
HeyfetsA., FlescherE. (2007) Cooperative cytotoxicity of methyl jasmonate with anti-cancer drugs and 2-deoxy-d-glucose. Cancer Letters, 250, 300–310.
27.
FingrutO., ReischerD., RotemR., GoldinN., AltboumI., Zan-BarI., FlescherE. (2005) Jasmonates induce nonapoptotic death in high-resistance mutant p53-expressing B-lymphoma cells. British Journal of Pharmacology, 146, 800–808.
28.
RavivZ., ZilberbergA., CohenS., Reischer-PelechD., HorrixC., BergerM.R., Rosin-ArbesfeldR., FlescherE. (2011) Methyl jasmonate down-regulates survivin expression and sensitizes colon carcinoma cells towards TRAIL-induced cytotoxicity. British Journal of Pharmacology, 164, 1433–1444.
29.
FarooqiA.A., ButtG., RazzaqZ. (2012) Algae extracts and methyl jasmonate anti-cancer activities in prostate cancer: choreographers of 'the dance macabre'. Cancer Cell International, DOI: 10.1186/1475-2867-12-50.
30.
DysonJ.K., RutterM.D. (2012) Colorectal cancer in inflammatory bowel disease: What is the real magnitude of the risk?World Journal of Gastroenterology, 18, 3839–3848.
